Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Plasma Fractionation market was valued at USD 29.5 billion in 2024 and is projected to reach USD 52.8 billion by 2031, exhibiting a CAGR of 8.1% during the forecast period.
Plasma fractionation involves the separation of blood plasma into its constituent components to produce life-saving therapies. This process yields essential products including immunoglobulins (used in immunodeficiency disorders), coagulation factors (for hemophilia treatment), albumin (for volume expansion in critical care), and other plasma-derived medicinal products. The global market continues to expand due to increasing demand for these specialized biologics across therapeutic areas.
Market growth is primarily driven by the rising prevalence of immunodeficiency disorders, hemophilia, and other bleeding disorders requiring long-term replacement therapy. The aging global population contributes significantly as older individuals show higher incidence rates for conditions requiring plasma-derived therapies. Furthermore, expanding applications in neurology, hematology, and critical care medicine continue to create new demand streams. However, challenges remain in plasma sourcing, regulatory harmonization, and high treatment costs particularly in developing regions.
The COVID-19 pandemic initially disrupted plasma collection due to social distancing measures, but also highlighted the critical importance of plasma-derived therapies in managing secondary infections and immune-related complications. The market has since rebounded strongly with increased plasma collection drives and improved fractionation technologies.
Rising Demand for Immunoglobulins
The global plasma fractionation market is experiencing significant growth due to increasing demand for immunoglobulins across various therapeutic areas. Immunoglobulin therapies are essential for treating immunodeficiency disorders, autoimmune diseases, and neurological conditions, driving consistent demand from healthcare providers worldwide.
Increasing Geriatric Population
With the global population aging at an unprecedented rate, the prevalence of age-related disorders requiring plasma-derived therapies continues to rise. This demographic shift creates sustained demand for plasma fractionation products and services, particularly in developed healthcare markets.
The plasma fractionation market is projected to reach $25.7 billion by 2028, growing at a CAGR of 6.8%
Market expansion is further accelerated by improved plasma collection infrastructure and increasing plasma donor participation programs across major markets.
MARKET CHALLENGES
High Production Costs and Complex Manufacturing
Plasma fractionation requires significant capital investment in specialized equipment and facilities. The complex manufacturing process, which includes multiple purification and viral inactivation steps, contributes to high operational costs that can impact market accessibility in developing regions.
Other Challenges
Regulatory Hurdles and Compliance Costs
The plasma fractionation industry faces stringent regulatory requirements across different regions, with varying standards for product approval and quality control. Compliance with Good Manufacturing Practices (GMP) and meeting FDA, EMA, and other regulatory requirements add considerable costs and complexity to market operations.
Supply Chain Vulnerabilities
Plasma fractionation relies on consistent plasma supply, which can be disrupted by various factors including donor availability, seasonal variations, and global health crises. These supply chain vulnerabilities create uncertainty and can restrain market growth during critical periods.
Emerging Markets Expansion
Developing economies present significant growth opportunities as healthcare infrastructure improves and demand for plasma-derived therapies increases. Countries with growing middle-class populations are creating new markets for plasma fractionation products and services.
Technological Advancements in Fractionation
Innovations in plasma fractionation technology, including improved purification techniques and more efficient fractionation processes, are creating opportunities for market expansion. These advancements enable higher yields, improved product quality, and reduced costs, making treatments more accessible globally.
Personalized Medicine Applications
The growing field of personalized medicine presents new opportunities for plasma-derived products. Customized therapies using plasma components for individual patient needs represent a growing market segment with significant potential for growth and innovation.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Immunoglobulins dominate the revenue share as they are essential for treating primary immunodeficiency diseases and autoimmune disorders, while coagulation factors maintain critical demand for hemophilia treatment and complex surgical procedures requiring hemostasis control. |
| By Application |
|
Hospitals and clinics represent the largest consumption segment due to direct patient care applications, while research institutes drive innovation through plasma-derived therapeutic research and diagnostic development, creating sustained demand across both clinical and research domains. |
| By End User |
|
Hospitals maintain the dominant position due to their central role in administering plasma-derived therapies for immune disorders, hemophilia, and critical care, while academic centers contribute through clinical trials and advanced treatment protocols development that expands the therapeutic applications. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
CSL Behring (USA) leads the plasma fractionation market with the broadest product portfolio and global distribution network, followed by Takeda Pharmaceutical (Japan) and Grifols (Spain) as close competitors in market share. These three companies collectively control over 60% of the global plasma fractionation market.
Emerging players such as Octapharma (Switzerland) and Kedrion (Italy) are gaining market share through strategic partnerships and regional expansion, particularly in the Asia-Pacific and Latin American markets where demand for plasma-derived therapies is growing rapidly.
Key players are investing heavily in R&D to develop next-generation plasma fractionation technologies, including pathogen reduction systems and more efficient purification processes. Takeda Pharmaceutical's recent $100 million investment in new fractionation facilities demonstrates the industry's commitment to expanding capacity.
Strategic acquisitions continue to shape the competitive landscape, with companies acquiring smaller plasma collection networks and specialty fractionators to vertically integrate their supply chains and secure plasma supply for fractionation.
List of Key Plasma Fractionation Companies ProfiledCSL Behring (USA)
Grifols S.A. (Spain)
Octapharma AG (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
Kedrion Biopharma (Italy)
China Biologic Products Holdings, Inc. (China)
The plasma fractionation market is experiencing significant growth driven by the increasing demand for immunoglobulin therapies across autoimmune and neurological disorders. Global immunoglobulin market is projected to reach $25.7 billion by 2028, growing at 7.3% CAGR.
Other TrendsExpansion in Emerging Markets
Emerging markets are becoming major growth drivers as healthcare infrastructure improves and regulatory pathways become more defined. Countries like China, India and Brazil are investing heavily in plasma collection infrastructure, with plasma collection centers growing at 15-20% annually in these regions.
Plasma collection initiatives have accelerated significantly, with the U.S. maintaining its position as the largest plasma supplier globally. The country accounts for approximately 70% of global plasma supply, with collection volumes growing at 8-10% annually. Europe and Asia-Pacific regions are also expanding their collection networks, driven by increasing demand for plasma-derived medicines.
Technological Advancements in Fractionation
New fractionation technologies are improving yield and efficiency, with several companies developing more sustainable and cost-effective processes. Advanced chromatography techniques and improved viral inactivation methods are becoming standard, contributing to better product recovery rates and reduced production costs.
The expansion of plasma-derived therapies into treatment of rare diseases continues to drive market growth. With over 7,000 rare diseases identified globally, many lack effective treatments, creating significant opportunities for plasma-derived therapies. Orphan drug designations and expedited regulatory pathways are supporting this growth segment.
Regional Analysis: Plasma Fractionation MarketEurope
Europe maintains a mature plasma fractionation market with well-established regulatory frameworks and reimbursement systems. The region features advanced Good Manufacturing Practice (GMP) compliance and invests in next-generation fractionation technologies. European manufacturers lead in developing sustainable fractionation processes with reduced environmental impact. Cross-border collaboration enables efficient plasma sourcing and distribution across the region.
Asia-Pacific
Asia-Pacific represents the fastest-growing plasma fractionation market, driven by increasing healthcare expenditure and rising diagnosis rates of primary immunodeficiency. Countries like Japan, Australia, and South Korea have implemented national strategies to develop domestic fractionation capacity while maintaining quality standards. The region shows strong growth in both plasma collection and fractionation throughput, with several new facilities under development.
Latin America
Latin American countries are developing coordinated approaches to plasma fractionation, with Brazil and Argentina leading in local production capabilities. The region benefits from plasma source diversification and increasing fractionation yields through process optimization. Regional partnerships enable technology transfer and capacity building while maintaining self-sufficiency goals.
Middle East & Africa
Middle Eastern countries are investing in plasma fractionation as part of broader healthcare infrastructure development. Gulf Cooperation Council (GCC) countries lead in establishing regional fractionation hubs while African nations focus on improving plasma collection networks. International partnerships facilitate technology transfer and local manufacturing development across the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global plasma fractionation market was valued at US$ 29.86 billion in 2024 and is expected to reach US$ 51.54 billion by 2031.
Which key companies operate in Global Plasma Fractionation Market?
-> Key players include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, and Hualan Bio, among others.
-> Key growth drivers include increasing demand for plasma-derived therapies, aging population, rising healthcare expenditure, and expansion of rare disease treatments.
-> North America is the largest market, while Asia-Pacific is the fastest-growing region.
-> Emerging trends include development of hyperimmune globulins, increased focus on rare diseases, and expansion of plasma collection networks.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates